Sleep Disorders

In this Peer Exchange, sleep experts provide insight into the latest narcolepsy treatments and areas that require further research.

Cancer centers providing care for adolescent and young adult cancer survivors may consider committing resources to routinely screen for sleep disorders and to support patient access to evidence-based insomnia treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

Neurology News Network for the week ending June 13, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 12, 2020.

After respective approvals in December 2019 and March 2020, lemborexant (Dayvigo; Eisai) and ozanimod (Zeposia; Bristol Myers Squibb) have become available for patients with insomnia and multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

Contrary to prior literature, a new single-center analysis suggests that obstructive sleep apnea is not associated with delirium in those who were postoperatively admitted to the ICU, though PAP may reduce delirium in this patient population.

Neurology News Network for the week ending May 16, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.

System interventions could be used to modify patient behavior, leading to improved adherence and better clinical outcomes for those with sleep-disordered breathing, according to new data.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 8, 2020.

The neurologist at Banner-University Medicine Neuroscience Institute discussed the findings of a study that suggest perampanel may improve insomnia by decreasing anxiety in patients with epilepsy.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine detailed the advancements that have been made with OSA treatment devices.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 1, 2020.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed new technologies being used to diagnose and treat sleep apnea.

Neurology News Network for the week ending April 25, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered her insight on how telemedicine is being utilized to help diagnose and treat sleep disorders amidst COVID-19.

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation.